

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

As of February 22, 2026

SUNDAY, MAY 3, 2026

15:00 *Welcome Coffee & Registration*

15:30 – 16:55 SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION I)

Chairs: **Jose Ángel Aibar**, *Madrid, Spain*
Emilio Perucca, *Melbourne, Australia*

15.30 **OPENING STATEMENTS**

15.40 THE NEUROBIOLOGY OF COMORBIDITIES IN DRAVET SYNDROME
Moran Rubinstein, *Tel-Aviv, Israel*

16.05 ADDRESSING GAPS IN GENETIC TESTING FOR DRAVET SYNDROME
Andreas Brunklaus, *Glasgow, UK*

16.30 UNDERSTANDING DISEASE MODIFICATION AND SYMPTOMATIC TREATMENTS FOR DRAVET SYNDROME
Simona Giorgi, *Elche, Spain*

16:55 *Coffee Break*

17:15 – 18:30 SYMPOSIUM HOSTED BY THE DRAVET SYNDROME FOUNDATION OF SPAIN (SESSION II)


Chairs: **Jose Ángel Aibar**, *Madrid, Spain*
Torbjörn Tomson, *Stockholm, Sweden*

17.15 OUTCOME MEASURES: "SEIZURES AND NON-SEIZURES" IN CLINICAL TRIALS OF TREATMENTS FOR DEEs
Elaine Wirrell, *Rochester, USA*

17.40 THE IMPORTANCE OF MULTIDISCIPLINARY MANAGEMENT IN DEEs
Stéphane Auvin, *Paris, France*

18.05 PATIENT-CENTERED HEALTHCARE: THE POWER OF PATIENT ADVOCACY
José Ángel Aibar, *Madrid, Spain*

18.30 **CLOSING REMARKS**



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026

08:15 – 08:30 **OPENING SESSION**
ORGANIZING COMMITTEE REMARKS AND GREETINGS
Meir Bialer, *Organizing Committee, Jerusalem, Israel*

GREETINGS

Emilio Perucca, *Organizing Committee and ILAE Past-President, Melbourne, Australia*

08:30 – 10:30 **Session 1: PRECLINICAL MODELS OF DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs): FROM SYMPTOMATIC TREATMENT TO DISEASE-MODIFYING AND PREVENTIVE STRATEGIES**

Chairs: **Heidrun Potschka**, *Munich, Germany*
Gabriele Lignani, *London, UK*

08:30 FACE AND PREDICTIVE VALIDITY OF DEE MODELS: BASIS FOR ROBUST ASSESSMENT OF ANTISEIZURE EFFECTS
Heidrun Potschka, *Munich, Germany*

08:50 Discussion

09:00 IT'S NOT ALL ABOUT SEIZURES: ASSESSMENT OF EFFECTS ON NON-SEIZURE SYMPTOMS IN DEE MODELS **Moran Rubinstein**, *Tel-Aviv, Israel*

09:20 Discussion


09:30 PRECISION MEDICINE APPROACHES FOR DEEs: TESTING STRATEGIES CONSIDERING SPECIES DIFFERENCES AND THE INFLUENCE OF GENETIC VARIANTS
Jack M. Parent, *Ann Arbor, USA*

09:50 Discussion

10:00 THE EARLIER – THE BETTER? - ASSESSMENT OF POSSIBLE DISEASE-MODIFYING AND PREVENTIVE STRATEGIES IN DEE MODELS
Gabriele Lignani, *London, UK*

10:20 Discussion

10:30 *Coffee Break*



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

11:00 – 13:30 Session 2: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Meir Bialer**, Jerusalem, Israel
Emilio Perucca, Melbourne, Australia

- 11:00 AUT00206
Charles Large, Autifony Therapeutics, UK
- 11:20 Discussion
- 11:30 BEXICASERIN (LP352)
Tolga Uz, Lundbeck Pharmaceuticals, Denmark
- 11:50 Discussion
- 12:00 BL-001
Louis Licamele, Bloom Science, USA
- 12:20 Discussion
- 12:30 RELUTRIGINE
Praxis Precision Medicines, USA
Presented by **Antonio Gil-Nagel**, Hospital Ruber Internacional, Spain
- 12:50 Discussion
- 13:00 BMB-101
Stephen Collins, Bright Minds Biosciences, USA
- 13:20 Discussion
- 13:30 Lunch Break

14:45 – 16:15 Session 3: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Piero Perucca**, Melbourne, Australia
Elaine Wirrell, Rochester, USA

- 14:45 Elsunersen
Steve Petrou, Praxis Precision Medicines, USA
- 15:05 Discussion
- 15:15 EPX -100
Amit Ray, Harmony Biosciences, USA
- 15:35 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

MONDAY, MAY 4, 2026, (Cont.)

- 15:45 ES-481
ES-Therapeutics, USA
Presented by **Terence O'Brien, Monash University, Australia**
- 16:05 Discussion
- 16:15 ETX101
Emma James, Encoded Therapeutics, USA
- 16:35 Discussion
- 16:45 Coffee Break

17:15 – 18:15 Session 4: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark, Sandvika, Norway**
Mathias Koepp, London, UK


- 17:15 ION283 ASO
Berge Minassian, University of Texas Southwestern, USA
- 17:35 Discussion
- 17:45 MSCA-7136
Brad Galer, Mosaica Medicines, USA
- 18:05 Discussion

TUESDAY, MAY 5, 2026

08:15 – 10:15 Session 5: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Torbjörn Tomson, Stockholm, Sweden**
H. Steve White, Seattle, USA

- 08:15 NRTX-1001
Eduardo Dunayevich, Neurona Therapeutics, USA
- 08:35 Discussion
- 08:45 Opakalim (BHV-7000)
Vivian Suarez, Biohaven Pharmaceuticals, USA
- 09:05 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

09:15 OV329
Julia Tsai, *Ovid Therapeutics, USA*

09:35 Discussion

09:45 *Coffee Break*

10:15- 12:45 Session 6: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Meir Bialer**, *Jerusalem, Israel*
Elaine Wirrell, *Rochester, USA*

10:15 PrevEp-006 (SELETRACETAM)
PrevEp, *USA*
Presented by **Wolfgang Löscher**, *Hannover Medical School, Germany and PrevEp, USA*

10:35 Discussion

10:45 PTI 5803
Panntherapi, *France*
Presented by **Gill Huberfeld**, *Hôpital Fondation Adolphe de Rothschild, France*

11:05 Discussion

11:15 RADIPRODIL
Russell L. Chin, *GRIN Therapeutics, USA*

11:35 Discussion

11:45 RAP 219
William Motley, *Rapport Therapeutics, USA*

12:05 Discussion


12:15 SN-2000
Deborah M Kurrasch, *Stream Neuroscience Inc, Canada*

12:35 Discussion

12:45 Lunch Break

14:00- 16:00 Session 7: NEW THERAPEUTIC AGENTS IN DEVELOPMENT

Chairs: **Cecilie Johannessen Landmark**, *Sandvika, Norway*
Piero Perucca, *Melbourne, Australia*



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

TUESDAY, MAY 5, 2026, (Cont.)

- 14:00 SODIUM SELENATE
Terence O'Brien, Monash University, Australia
- 14:20 Discussion
- 14:30 SVG103
Sovargen Co, Republic of Korea
Presented by **Hing-Ho Lee, Korea Advanced Institute of Science and Technology (KAIST)**
and **Sovargen Co, Republic of Korea**
- 14:50 Discussion
- 15:00 SYNGAP 1 ASO (CMP-002)
Yuri Maricich, CAMP4 Therapeutics, USA
- 15:20 Discussion
- 15:30 *Coffee Break*

16:00 – 17:00 Session 8: NEW THERAPEUTIC AGENTS IN DEVELOPMENT


Chairs: **Emilio Perucca, Melbourne, Australia**
H. Steve White, Seattle, USA

- 16:00 VORMATRIGINE (PRAX-628)
Presented by **Steve Petrou, Praxis Precision Medicines, USA** and
Angel Aledo-Serrano Clinical Neuroscience Institute (Blua Sanitas Valdebebas Hospita), Spain
- 16:20 Discussion
- 16:30 ZOREVUNERSEN (STK-001)
Carolyn Reeve, Biogen, USA
- 16:50 Discussion

17:00 – 18:00 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION

Chairs: **Meir Bialer, Jerusalem, Israel**
Torbjörn Tomson, Stockholm, Sweden

- 17:00 DIAZEPAM NASAL SPRAY
Stella Ngo, Neurelis, USA
- 17:20 Discussion
- 17:30 PRECLINICAL AND CLINICAL EVIDENCE IN SUPPORT OF A DISEASE MODIFYING EFFECT OF DIAZEPAM TREATMENT ON SEIZURE CLUSTERS
Presented by **Steve White, School of Pharmacy, University of Washington, USA**
- 17:50 Discussion



Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026

08:15 – 09:15 Session 9: INNOVATIVE ROUTES OF RESCUE MEDICATION cont.

- 08:15 BUCCAL MIDAZOLAM
Neuraxpharm, Spain
Presented by **Federico Vigeveno, IRCCS San Raffaele and LUMSA University, Italy**
- 08:35 Discussion
- 08:45 STACCATO ALPRAZOLAM
Robert Roebing, UCB Pharma, Belgium
- 09:05 Discussion

09:15-11:45 Session 10: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE MEDICATIONS


Chairs: **Cecilie Johannessen Landmark, Sandvika, Norway**
Emilio Perucca, Melbourne, Australia

- 09:15 BRIVARACETAM
Brian Moseley, UCB Pharma, Belgium
- 09:35 Discussion
- 09:45 CENOBAMATE
John Paul Leach, Angelini Pharma Group, Italy
- 10:05 Discussion
- 10:15 Coffee Break
- 10:45 FENFLURAMINE
Brian Moseley, UCB Pharma, Belgium
- 11:05 Discussion
- 11:15 GANAXOLONE
Immedica Pharma, Sweden
Presented by **Nicola Specchio, Bambino Gesù, Children Hospital, IRCCS, Italy**
- 11:35 Discussion

11:45-13:15 Session 11: PROGRESS REPORT ON RECENTLY MARKETED ANTISEIZURE DEVICES

Chairs **Mathias Koepp, London, UK**
Piero Perucca, Melbourne, Australia

- 11:45 FOCAL CORTEX STIMULATION
Precisis, Germany
Presented by **Andreas Schulze-Bonhage, University of Freiburg, Germany**
- 12:05 Discussion



Secretariat: Comtecmed

Rothschild Boulevard 53, P.O Box 68 Tel Aviv 6578501 Israel | Tel: +972-3-5666166 | eilat@comtecmed.com

Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII)

May 3-6, 2026

MADRID, SPAIN

ORGANIZING COMMITTEE

M. Bialer, Israel

C. Johannessen Landmark, Norway

M. Koepp, UK

E. Perucca, Australia

P. Perucca, Australia

T. Tomson, Sweden

H.S. White, USA

E.C. Wirrell, USA

WEDNESDAY, MAY 6, 2026, (Cont.)

12:15 **RESPONSIVE NEUROSTIMULATION**
Martha Morrell, Neuropace, USA

12:35 Discussion

12:45 **VAGUS NERVE STIMULATION**
Maxine Dibué-Adjei, LivaNova, UK

13:05 Discussion

13:15 Lunch Break

14:30 – 17:00 Session 12: DEVELOPING STATE-OF-THE-ART THERAPIES FOR DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEEs)

Chairs: **Andreas Bruncklaus, Glasgow, UK**
 Elaine Wirrell, Rochester, USA

14:30 **SELECTING POPULATIONS FOR TRIALS OF ANTISEIZURE MEDICATIONS (ASMs) FOR DEEs**
– SHOULD WE LUMP OR SPLIT?
Elaine Wirrell, Rochester, USA

14:50 Discussion

15:00 **MEASURING NONSEIZURE OUTCOMES IN CLINICAL TRIALS IN DEEs**
J. Helen Cross, London, UK

15:20 Discussion

15:30 **WHAT IS MEANT BY “DISEASE MODIFYING” AND HOW DO WE PROVE THAT?**
Stephane Auvin, Paris, France

15:50 Discussion

16:00 **METHODOLOGICAL CHALLENGES IN DEVELOPING GENE THERAPIES FOR DEEs**
Andreas Bruncklaus, Glasgow, UK

16:20 Discussion

16:30 Closing Remarks

